AEAbdallah Essa

Abdallah Essa

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Abdallah Essa has a total of 66 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    First‐Line Levofloxacin‐Based Triple Therapy Versus Standard Bismuth‐Based Quadruple Therapy for Helicobacter pylori Eradication in Saudi Arabia: A Retrospective Single‐Center Study

    by Abdulrhman Khaled Al Abdulqader, Turki Abdullah Alamri, Mahdi Abdullah Alhamad, Somaia Shehab El‐Deen, Abdallah Essa, Raed Abdullah Alfayez, Baqer Mohammed Albaqshi, Adnan Salah Almajed, Mohammed Yousef Alhassan, Ali Essa, et al.

    Background and Aims: Antibiotic resistance in Saudi Arabia has led to decreased efficacy of conventional triple therapy for Helicobacter pylori (H. pylori) eradication, prompting the development of alternative treatments like levofloxacin‐based triple and bismuth‐based quadruple therapies. However, comparative data regarding its efficacy are lacking. Therefore, this study's goal was to compare the efficacy of levofloxacin‐based triple therapy with that of standard bismuth‐based quadruple therapy as first‐line regimens.Methods: This retrospective analysis included 197 treatment‐naïve adults with H. pylori infection who received levofloxacin‐based triple (levofloxacin + amoxicillin + PPI) therapy (n = 81) or standard bismuth‐based quadruple (bismuth + tetracycline + metronidazole + PPI) therapy (n = 116). H. pylori eradication was evaluated 4–8 weeks after medication administration using the 13C‐urea breath test, and variables that could affect the rate of success were examined.Results: There were no differences between groups in terms of age, sex, nationality, or type of proton pump inhibitor (PPI) used. The bismuth‐based quadruple therapy group exhibited a markedly superior success rate compared to the levofloxacin‐based triple therapy group when the latter was administered for 7 or 10 days (81.03% vs. 6.66%, p < 0.001, and 81.03% vs. 36.1%, p < 0.001, respectively). However, when the levofloxacin‐based triple therapy was extended to 14 days, its H. pylori eradication rate became comparable to that of the 10‐day bismuth‐based quadruple therapy (81.03% vs. 80%, p = 0.898). Eradication rates for both regimens were similar for patients aged ≥ 60, non‐Saudi, when using omeprazole and those treated with levofloxacin‐based triple therapy for 14 days.Conclusion: Quadruple treatment based on bismuth is superior to triple therapy based on levofloxacin for eradicating H. pylori in Saudi Arabia and should be used as a first‐line treatment. However, the 14‐day levofloxacin‐based triple treatment had an H. pylori eradication rate comparable to that of the 10‐day bismuth‐based quadruple therapy.


  • Open Access

    Gastroesophageal Reflux Disease Among Undergraduate Medical Students in Egypt: Prevalence and Risk Factors

    by Ali Essa, Ahmed Nasser, Ibrahim Noureldeen, Ibrahim Ebeid, Ahmed Ebeid, Baraa Ahmed, Heba Allam, Somaia Shehab-Eldeen, Abdallah Essa

    Background: Gastroesophageal reflux disease (GERD) is a prevalent gastrointestinal condition that has a detrimental impact on one's quality of life because of acid reflux causing damage to the esophagus. Primary symptoms consist of heartburn and regurgitation, although patients may also encounter chest pain, nausea, and dysphagia. Medical students may be particularly susceptible due to stressful lifestyles and unhealthy habits. This study investigates the prevalence of GERD among medical students in Egypt and explores associated risk factors. Subjects and Methods: This is a cross-sectional observational study that was conducted among undergraduate medical students at 21 medical schools across Egypt. The study included 602 participants from medical schools. The study utilized a pre-designed, selfadministered questionnaire that includes questions about sociodemographic and lifestyle attributes, accompanied by the GERDQ questionnaire used to diagnose gastroesophageal reflux disease. Results: A total of 602 undergraduate medical students completed the questionnaire. The prevalence of GERD was found to be 28.4%, with heartburn and regurgitation being the most prevalent symptoms among participants. Univariate and multivariate logistic regression revealed family history of GERD and stress after medical school enrollment as significant predictors of GERD symptoms (p=0.043 and p=0.044, respectively). Conclusion: GERD has become increasingly common among medical students in Egypt. Contributing factors include medical students' stressful lifestyles and familial predispositions. To address this, it is essential to implement counseling programs and raise awareness as initial steps toward reducing GERD prevalence.


  • Open Access

    Serum LINC00152 and UCA1 in HCV-Induced Hepatocellular Carcinoma: Clinical Significance and Prognostic Value

    by Somaia Shehab-Eldeen, Abdallah Essa, Eman Salah Arafat, Asmaa Shaaban Sleem, Amal Abdelrasoul Alhosary, Ehab Darwish, Ali Essa, Omar Ahmed Al-Omair, Emad Ali Al-Khoufi, Abdulrhman Khaled Al Abdulqader, et al.

    Background: Despite significant advancements in the molecular characterization of hepatocellular carcinoma (HCC), no oncogene addiction has been discovered. Long noncoding RNAs (lncRNAs) have a lot of promise as cancer biomarkers. LINC00152 and UCA1 have shown potential as diagnostic, prognostic, and therapeutic targets for human cancers. Aim: To investigate the diagnostic and prognostic potential of serum LINC00152 and UCA1 in hepatocellular carcinoma (HCC). Methods: The expression levels of LINC00152 and UCA1 in blood samples from 120 patients (60 with HCC, 60 with liver cirrhosis) and 40 healthy subjects were assessed using real-time qRT-PCR. Results: Serum LINC00152 and UCA1 expression were considerably higher in HCC patients compared to patients with liver cirrhosis and the healthy controls (p< 0.001 and p< 0.001 respectively). And their expressions in the liver cirrhosis group were significantly higher than in healthy controls. Both lncRNAs performed well in the ROC analysis, distinguishing HCC patients from patients with liver cirrhosis. Higher levels of LINC00152 expression were linked to lesions in both lobes of the liver (p=0.02), while higher levels of UCA1 expression were linked to vascular invasion and the late stage (p=0.01, p=0.03 respectively). The multivariate analysis showed that a high level of LINC00152 in the blood was an independent indicator of a bad outcome for HCC patients (HR=2.23, 95% CI= 1.30– 5.29, p=0.03). Conclusion: Serum LINC00152 and UCA1 expression were upregulated in patients with HCC, suggesting their use as non-invasive biomarkers for HCC. Furthermore, LINC00152 has the potential to serve as a prognostic indicator.


  • Open Access

    Factors Affecting Hospitalization Length and in-Hospital Death Due to COVID-19 Infection in Saudi Arabia: A Single-Center Retrospective Analysis

    by Omar A Al Omair, Abdallah Essa, Khaled Elzorkany, Somaia Shehab-Eldeen, Hamzah M Alarfaj, Sumaia M Alarfaj, Fatimah Alabdulqader, Alghaydaa Aldoughan, Mohammed Agha, Sayed I Ali, et al.

    Background: The emerging COVID-19 coronavirus disease has widely spread, causing a serious worldwide pandemic. Disease severity and mortality risk can be predicted using an analysis of COVID-19 clinical characteristics. Finding out what influences patients’ hospitalization length and in-hospital mortality is crucial for decision-making and planning for emergencies. The goal of this study is to identify the factors that influence hospital stay length and in-hospital death due to COVID-19 infection. Methods: This cross-sectional study was conducted from August to October 2020 and included 630 patients with a confirmed diagnosis of COVID-19 infection. Using odds ratios (OR) and 95% confidence intervals (CI), a multivariable logistic regression model was used to assess the variables that are linked to longer hospital stays and in-hospital deaths. Results: Most patients were male (64.3%), and most were older than 40 years (81.4%). The mean length of hospital stay (LoHS) was 10.4± 11.6 days. The overall death rate among these COVID-19 cases was 14.3%. Non-survivors were older, had more comorbidities, had prolonged LoHS with increased ICU admission rates and mechanical ventilation usage, and had a more severe condition than survivors. ICU admission, low serum albumin, and elevated LDH levels were associated with longer LoHS, while ICU admission, DM, and respiratory diseases as comorbidities, total leukocytic count, and serum albumin were predictors of mortality. Conclusion: Longer LoHS due to COVID-19 infection was linked to ICU admission, low serum albumin, and elevated LDH levels, while the independent predictors of in-hospital death were ICU admission, DM, and respiratory diseases as comorbidities, total leukocytic count, and serum albumin.


  • Open Access

    Evaluation of liver stiffness by non-invasive methods after eradication of HCV by direct-acting antiviral therapy: a retrospective observational study

    by Alaaudin Habib, Somaia Shehab-Eldeen, Abdallah Essa, Ahmed M. Albeltagy, Mahmoud Awad

    Background: There is some debate about the effect of direct-acting antiviral regimens (DAAs) on regression of liver fibrosis, but no definitive conclusion has been reached. The aim of this study is to evaluate liver stiffness measurement changes after attaining sustained virologic response (SVR) for HCV following DAAs treatment using non-invasive methods. Methods: This retrospective study analyzed 84 patients with chronic HCV infection who were treated with DAAs and achieved SVR after treatment. At baseline and 24 weeks post sustained virologic response (SVR24), transient elastography values were obtained and the Fibrosis-4 score (FIB-4) and AST to Platelet Ratio Index (APRI) were calculated. Results: Compared to baseline data, patients achieved SVR following DAAs treatment showed significant decrease in liver stiffness measurement at SVR24 (16.6±12.6 vs 12.6 ± 11.6 kPa) (P<0.01) with significant fibrosis down staging in the majority of patients. Furthermore, there was a significant improvement as regarding, FIB-4 and APRI scores at SVR24 (2.1±1.9 vs 5.1 ± 2.3 and 0.33 ± 0.2 vs 0.93 ± 0.4 respectively, P <0.001). Conclusion: DAAs treatment significantly improved liver stiffness as measured by FibroScan. Further, multicenter prospective studies with histopathologic correlations are needed to clarify the impact of DAAs on the improvement of necroinflammation and fibrosis.

  • Open Access

    Splenectomy perspective for non-malignant hematological disorders: A cross-sectional study in the Eastern Province of KSA

    by Mortadah H. Alsalman, Faisal A. Al Jabr, Samma T. Eraqe, Sayed I. Ali, Abdallah Essa


  • Open Access

    Value of Serum miRNA-96-5p and miRNA-99a-5p as Diagnostic Biomarkers for Hepatocellular Carcinoma

    by Amal F Gharib, Emad M Eed, Amany S Khalifa, Nermin Raafat, Somaia Shehab-Eldeen, Hany R Alwakeel, Ehab Darwiesh, Abdallah Essa

    Purpose: Circulatory microRNAs (miRNAs) have the potential to be employed as markers for cancer detection and as prognostic tools for disease management. As a result, our goal was to explore the effectiveness of serum miRNA-96-5p and miRNA-99a-5p as diagnostic tools in hepatocellular carcinoma (HCC). Patients and methods: Blood samples were collected from 55 patients with HCV-induced HCC, 55 patients with HCV-induced liver cirrhosis, and 55 healthy controls. The expression levels of miRNA-96-5p and miRNA-99a-5p were measured using quantitative RT-PCR. Results: miRNA-96-5p expression levels were increased in HCC patient sera, while miRNA-99a-5p levels were reduced. According to ROC curve analysis, using a combination of circulating miRNA-96-5p, miRNA-99a-5-, and alpha-fetoprotein (AFP) improves the accuracy of diagnoses for HCC, with an area under the curve (AUC) of 0.97, compared to AUCs of 0.82, 0.86, and 0.73, respectively, for the individual biomarkers. Furthermore, the present data suggested that higher serum miRNA-96-5p levels were linked to larger tumors and metastasis, whereas lower serum miRNA-99a-5p levels were exclusively linked to HCC metastasis. Conclusion: Using miRNA-96-5p and miRNA-99a-5p in combination with AFP increased both sensitivity and specificity for the diagnosis of HCC. Furthermore, serum levels were linked to tumor size and metastasis. These findings suggested that serum miRNA-96-5p and miRNA-99a-5p could be used as non-invasive biomarkers for the diagnosis of HCC.


  • Open Access

    Serum microRNA 106 and microRNA 223 as novel biomarkers in inflammatory bowel disease

    by Alaa Habib, Ayman Minisi, Mahmoud Awad, Abdallah Essa, Amany Khalifa, Somaia Shehab-Eldeen

    Background: Inflammatory bowel disease (IBD) involves mainly Crohn’s disease (CD) and ulcerative colitis (UC). Distinguishing between the two dise-ases may be problematic in 15% of patients due to inconclusive findings on histopathology or endos-copy. miRNAs are non-coding RNAs composed of 18-23 nucleotides and are widely detected in the cells involved in variable pathological and physiological processes. The aim of this study is to assess if serum microRNA 106 and microRNA 223 (miR-223) can be reliable biomarkers in IBD patients. Methods: Serum levels of microRNA 106 and microRNA 223 (miR-223) were determined in 80 IBD patients by using the Transcript or First Stand cDNA, expression levels of serum miRNA in IBD patients and the control group and between active and inactive diseases were detected. Results: There was a significant increase in expression levels of serum miRNA 106 and miRNA 223 in IBD patients (UC and CD) compared to the control group (P<0.001, both). Also, There was a significant incr-ease of expression levels of serum miRNA 106 and serum miRNA 223 with increased disease activity of IBD (P <0.05, both). Conclusions: The levels of miRNA 106 and miRNA 223 are higher in the peripheral blood of IBD patients and the elevation is more significant in the active disease. The miRNA 106 and miRNA 223 may be used as a novel biomarker in the diagnosis of IBD and evaluating the disease activity.


    • 9 November 2016
      • Vol. 79  (3) , 309-313

    DKK1 in relation to HCV induced liver cirrhosis and HCV induced HCC curative resection.

    by E S Essa, B A Montaser, M T Badawy, Abdallah Essa, M S Mokhtar

    Hepatitis C virus (HCV) is an RNA virus that induces hepatocarcinogenesis by mechanisms other than integration in the host cell genome. Dickkopf-1 (DKK1) expression has been studied mostly in hepatitis B virus induced HCC but not properly investigated in HCV induced HCC. Aim: we aimed to assess serum DKK1 in HCV induced HCC, HCV induced liver cirrhosis and viral infection-free controls. Moreover, we assessed serum DKK1 level after curative resection of HCC.. Serum DKK1 was measured by ELISA in 20 HCV induced HCC patients; both pre-resection and post-resection, 20 HCV induced liver cirrhosis patients and 20 viral infection-free controls. DKK1 levels were significantly higher in HCC than cirrhosis patients (P = 0.000). DKK1 did not differ significantly between cirrhotic patients and controls (P = 0.11). DKK1 levels significantly reduced 5 days post-resection compared to their pre-resection levels (P = 0.000). We documented serum DKK1 as a marker for detection of early HCC in HCV infected patients. Significant reduction of DKK1 5 days after curative resection might indicated it as a follow up marker for recurrence in surgically resected HCV induced HCC patients. Larger scale studies to follow up its level at various intervals postoperatively and evaluate its pre-resection level as a prognostic marker in HCV induced HCC patients will be needed. (Acta gastro-enterol. belg., 2016, 79, 309-313).


  • Serum PAI-1 and PAI-1 4G/5G Polymorphism in Hepatitis C Virus-Induced Cirrhosis and Hepatitis C Virus-Induced Hepatocellular Carcinoma Patients

    by Rawhia H. El Edel, Enas Said Essa, Abdallah S. Essa, Sara A. Hegazy, Dalia I. El Rowedy

    Association between variable agent-induced hepatocellular carcinoma (HCC) and both PAI-1 4G/5G polymorphism and plasminogen activator inhibitor (PAI-1) levels compared to healthy controls have been reported in earlier studies. We aimed to assess serum PAI-1 and PAI-1 4G/5G polymorphism in hepatitis C virus (HCV)-induced HCC, HCV-induced liver cirrhosis, and viral infection-free apparently healthy control subjects. Forty nine HCC, 52 cirrhosis, and 105 controls were genotyped for PAI-1 4G/5G using an allele-specific polymerase chain reaction analysis. In addition, for 31 HCC, 24 cirrhosis, and 28 controls, serum PAI-1 level was measured by enzyme-linked immunosorbent assay (ELISA). There was no significant difference in PAI-1 4G/5G genotype distribution between cirrhosis and controls (p = 0.33, p = 0.15, and p = 0.38 for the codominant, dominant, and recessive models, respectively) or between HCC and cirrhosis (p = 0.5, p = 0.24, and p = 0.69 for the codominant, dominant, and recessive models, respectively). Serum PAI-1 was significantly higher in cirrhosis than controls and significantly lower in HCC than cirrhosis (p < 0.001 for both). Serum PAI-1 did not differ significantly among the three PAI-1 4G/5G genotypes in controls, cirrhosis, and HCC (p = 0.29, p = 0.28, and p = 0.73 respectively). We documented higher serum PAI-1 in HCV-induced HCC than viral infection-free controls, but interestingly, lower than HCV-induced liver cirrhosis patients. This was not genotype related. Further studies will be needed to clearly elucidate the underlying mechanism.